In July 2018, the following letters were sent from licence holders to healthcare professionals about the safety of medicines:
Valproate (Epilim▼, Depakote▼): new restrictions on use;
(for specialists and specialist nurses managing patients treated with valproate medicines and general practitioners who provide primary care to these patients)
Valproate (Epilim▼, Depakote▼): new restrictions on use: pregnancy prevention programme;
In July 2018, MHRA issued the following Alerts and recalls for drugs:
Please continue to submit your thoughts on how we can improve the communication of medicines safety issues to support safe and effective use through this 10-minute survey.
Article citation: Drug Safety Update volume 12, issue 1; August 2018: 2.